Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

532
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
532
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.9K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.9K
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

873
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
873
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

568
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
568
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

1.4K
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.4K
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

718
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
718

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Health Care Use and Outcomes in Heart Failure: Are There Lingering Impacts From the COVID-19 Pandemic?

JACC. Advances·2026
Same author

Patient-physician familiarity is just as important for virtual outpatient encounters as for in-person encounters: a retrospective cohort study.

Scientific reports·2026
Same author

New and persistent psychoactive medication use in intensive care unit survivors with COVID-19: a multicentre population-based cohort study.

Canadian journal of anaesthesia = Journal canadien d'anesthesie·2026
Same author

Changes in Hypertension Prevalence and Control in Canada After the COVID-19 Pandemic: Insights From the Canadian Health Measures Survey Cycle 7.

The Canadian journal of cardiology·2026
Same author

Machine learning model for predicting improvement in left ventricular systolic function in patients with heart failure and reduced ejection fraction.

International journal of cardiology. Heart & vasculature·2026
Same author

Validation of International Classification of Diseases Code-Based Case Definitions of Immune Checkpoint Inhibitor-Associated Inflammatory Arthritis From Administrative Health Data.

Arthritis & rheumatology (Hoboken, N.J.)·2026

Related Experiment Video

Updated: Mar 31, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K

Outcomes and Patterns Related to Magnesium in Acute Heart Failure: A Population-Based Study.

Robert Margaryan1, Sunjidatul Islam1, Douglas Dover1

  • 1Canadian VIGOUR Centre, University of Alberta, Edmonton, Alberta, Canada.

The Canadian Journal of Cardiology
|March 29, 2026
PubMed
Summary

Magnesium testing is common in heart failure (HF) patients, with abnormal levels linked to worse outcomes. Intravenous magnesium replacement showed increased short-term mortality and hospitalization risks in this study.

Keywords:
acute heart failurehypomagnesemiaintravenous magnesiumretrospective studies

More Related Videos

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices
11:19

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices

Published on: May 10, 2020

11.6K
Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

6.3K

Related Experiment Videos

Last Updated: Mar 31, 2026

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs
14:35

Post-Myocardial Infarction Heart Failure in Closed-chest Coronary Occlusion/Reperfusion Model in Göttingen Minipigs and Landrace Pigs

Published on: April 17, 2021

9.3K
Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices
11:19

Isolation of Human Ventricular Cardiomyocytes from Vibratome-Cut Myocardial Slices

Published on: May 10, 2020

11.6K
Magnetic Adjustment of Afterload in Engineered Heart Tissues
09:40

Magnetic Adjustment of Afterload in Engineered Heart Tissues

Published on: May 5, 2020

6.3K

Area of Science:

  • Cardiology
  • Clinical Chemistry
  • Pharmacology

Background:

  • The role of magnesium in heart failure (HF) management and prognosis is not well-defined.
  • Magnesium testing and treatment are frequently employed in HF care.
  • Uncertainty exists regarding the impact of magnesium levels and interventions on HF outcomes.

Purpose of the Study:

  • To investigate the frequency of serum magnesium testing in acute heart failure (HF) patients.
  • To determine the association between magnesium levels (hypomagnesemia and hypermagnesemia) and HF outcomes.
  • To evaluate the impact of intravenous (IV) magnesium replacement on mortality and hospitalization in HF patients.

Main Methods:

  • Retrospective cohort study utilizing linked administrative data from April 2012 to March 2020.
  • Inclusion of patients with a primary diagnosis of acute heart failure (HF) in emergency departments or hospitals.
  • Analysis of outcomes including all-cause mortality, cause-specific death, hospitalization, emergency department visits, and physician claims, alongside magnesium testing rates and hypomagnesemia prevalence.

Main Results:

  • Serum magnesium testing was performed in 58.7% of 78,957 acute HF episodes.
  • Abnormal magnesium levels (<0.75 mmol/L or >0.95 mmol/L) were observed in 31.7% and 11.5% of tested patients, respectively.
  • Both low (<0.70 mmol/L) and high (>0.86 mmol/L) magnesium levels were independently associated with increased mortality.
  • Intravenous (IV) magnesium administration, given to 13.7% of tested patients, was associated with higher short-term mortality (HR 1.66) and hospitalization risk (HR 1.36) after multivariable adjustment.

Conclusions:

  • Serum magnesium testing is prevalent in acute heart failure (HF) presentations.
  • Both low and high serum magnesium levels correlate with adverse outcomes in HF patients.
  • Intravenous magnesium replacement appears linked to worse short-term outcomes, necessitating further investigation.